Alopecia areata universalis during off-label treatment with Infliximab in a patient with Behçet disease.
Infliximab, a chimeric monoclonal anti-TNF-alfa agent used to treat autoimmune diseases, has shown a paradoxical side effect in the development of autoimmunity. We describe a case of alopecia areata universalis associated with infliximab treatment in a patient with Behçet disease. This case suggests a complex and contradictory role of TNF-α in the pathogenesis of alopecia areata.
Beccastrini
E
E
Squatrito
D
D
Emmi
G
G
Fabbri
P
P
Emmi
L
L
D000328:Adult; D000506:Alopecia Areata / Q000139:chemically induced* / Q000276:immunology; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000139:chemically induced* / Q000276:immunology; D001528:Behcet Syndrome / Q000188:drug therapy; D006801:Humans; D000069285:Infliximab; D008297:Male; D056687:Off-Label Use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab